A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients with Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Pinometostat (Primary)
- Indications Acute myeloid leukaemia; Leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Proof of concept
- Sponsors Epizyme
- 06 Dec 2016 Final results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 02 Aug 2016 Status changed from active, no longer recruiting to completed.
- 06 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.